Sun Yat-sen University Cancer Center

Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi)

<title>Abstract</title> Background PARP inhibitors (PARPi) are standard front-line maintenance therapy for advanced ovarian cancer, but the efficacy of PARPi retreatment in later lines remains unclear. This phase Ib/II study evaluated the combination of pamiparib (a PARPi) and su...

Development of a urine-based DNA methylation assay for early endometrial cancer detection: a multicenter diagnostic study

Endometrial cancer (EC) incidence is rising globally, yet diagnosis still depends on invasive procedures, which limit accessibility and delay early detection. A noninvasive, accurate, and accessible diagnostic assay is urgently needed to enable early EC detection. In this multice...

Development and multicenter validation of a predictive nomogram for infection risk in patients with multiple myeloma

To explore the key influencing factors of the risk of nosocomial infection in patients with multiple myeloma (MM), to construct a prediction model to effectively assess the risk of infection, and to provide a basis for individualized infection prevention and control. 245 patients...

EBV-driven Gate–License–Amplify circuit in multiple sclerosis pathogenesis

Five recent publications establish a “Gate–License–Amplify” circuit that mechanistically links Epstein–Barr virus (EBV) infection and genetic risk (HLA-DR15) to the pathogenesis of multiple sclerosis (MS). 1 , 2 , 3 , 4 , 5 This new model reveals how EBV reprograms immunopeptidom...

Proximal ProteomicsReveals Potential Regulators ofProgrammed Death-Ligand 1 in Human Cancer

Abstract Programmed death-ligand 1 (PD-L1) is a key mediator of tumor immune evasion, but the protein networks governing its post-translational regulation remain incompletely understood. Here, we used PhastID-based proximity labeling to map the PD-L1 proximal proteome and integra...

Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations

Importance: Combination therapy has emerged as a promising therapeutic approach for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, its clinical benefit-risk profile remains a focus of ongoing debate. Identifying patients...

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy is largely ineffective in most solid tumors, partially because of inadequate intratumoral trafficking. Bridging therapy, administered between leukapheresis and CAR‐T cell infusion, offers a distinct opportunity to control th...

Efficacy of anti-PD-1/PD-L1 plus chemotherapy in treatment-naïve advanced HER2-negative gastric adenocarcinoma among different PD-L1 intervals: an updated meta-analysis and reconstructed individual patient-level data analysis

Abstract Background Chemo-immunotherapy (CIT) has become the frontline therapy for advanced human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-esophageal junction adenocarcinoma (GEAC). However, emerging evidence suggests that clinical benefit is primarily...

p38β-mediated BiP phosphorylation drives stemness and chemoresistance by suppressing UPR activation in hepatocellular carcinoma

Abstract Tumor-initiating cells (TICs) promote tumor initiation and therapy resistance, yet the kinase regulators that sustain TICs remain incompletely defined. Here, we identify the stress kinase p38β (MAPK11) supports TIC maintenance and drug resistance in hepatocellular carcin...

Time-dependent anti-Müllerian hormone dynamics during GnRHa-based endocrine therapy in young breast cancer survivors: a longitudinal real-world cohort study

Abstract Background Anti-Müllerian hormone (AMH) is widely used to assess ovarian reserve in young women with breast cancer. However, its interpretation during gonadotropin-releasing hormone agonist (GnRHa)-based endocrine therapy remains challenging because pharmacologic ovarian...

IL10RB-AS1 promotes pro-caspase-1-dependent pyroptosis via regulating the oligomerization and nucleation of CARD8 C-terminal domain to suppress acute myeloid leukemia

Abstract CARD8 (caspase activation and recruitment domain-containing 8) senses intracellular danger signals, leading to inflammasome formation and pyroptosis. Recently studies have shown that CARD8 was highly expressed in hematopoietic cells, however, the mechanism by which the r...